Q2 2025 Inovio Pharmaceuticals Inc Earnings Call Transcript

Aug 12, 2025 / 08:30 PM GMT

Release Date Price: MXN27

Transcript 8-K10-Q

Key Points

Positve

Inovio Pharmaceuticals Inc (INO) is on track to submit its BLA for INO 3,107 in the second half of 2025, with the goal of file acceptance by year-end.
The company has completed the design verification testing of its Selecttra 5 PSP device, a key milestone for regulatory progress.
INO 3,107 has been granted breakthrough therapy designation by the FDA, allowing for a rolling submission of the BLA.
Clinical data from INO 3,107 has been published in reputable journals, supporting its potential as a preferred treatment for RRP.
Inovio Pharmaceuticals Inc (INO) has significantly reduced its operating expenses by 31% year-over-year, demonstrating fiscal responsibility.

Negative

Inovio Pharmaceuticals Inc (INO) experienced a decrease in cash equivalents and short-term investments, from $94.1 million at the end of 2024 to $47.5 million by mid-2025.
The company anticipates an operational net cash burn of approximately $22 million for the third quarter of 2025.
There is uncertainty regarding the potential need for an advisory committee meeting for the BLA submission, which could impact timelines.
The company faces competition from other treatments in the RRP space, which could affect market share and enrollment in confirmatory trials.
Inovio Pharmaceuticals Inc (INO) has not provided specific guidance on the size of its commercial organization, which may impact its ability to effectively launch INO 3,107.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

INO.OQ - Inovio Pharmaceuticals Inc
Q2 2025 Inovio Pharmaceuticals Inc Earnings Call
Aug 12, 2025 / 08:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good afternoon ladies and gentlemen, and welcome to the Novio 2nd quarter 2025 Financial results conference call.

At this time, all lines are in listen-only mode.

Following the presentation, we will conduct a question and answer session.

If at any time during this call you require immediate assistance, please press 0 for the operator.

This call is being recorded on Tuesday, August 12, 2025.

I would now like to turn a conference over to Jenny Wilson. Please go ahead.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Good

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.